Caribou Biosciences Stock Rises 3% After Dual Positive Phase 1 Trial Updates

(RTTNews) - Caribou Biosciences, Inc. (CRBU) climbed 3.34% to $2.5010, up $0.0810, following the release of positive clinical data from both its ANTLER and CaMMouflage Phase 1 trials.

The company announced that its allogeneic anti-CD19 CAR-T therapy (vispa-cel/CB-010) achieved an 82 percent overall response rate (ORR) and 64 percent complete response (CR) rate in the 22-patient confirmatory cohort of the ANTLER trial.

Additionally, its allogeneic anti-BCMA CAR-T therapy (CB-011) in the CaMMouflage trial delivered an ORR of 92 percent, CR/sCR rate of 75 percent, and MRD negativity of 91 percent (in 11/12 evaluable BCMA-naïve patients) at the recommended dose for expansion.

Caribou said it will initiate the dose expansion of CB-011 before year-end and plans to design a pivotal Phase 3 trial for vispa-cel in 2L LBCL patients in alignment with the U.S. Food & Drug Administration.

On the day of the news, CRBU opened near $2.45, reached a high of $2.60, and a low of $2.40, compared to the previous close of $2.4200. Trading volume surged significantly (exact volume data pending) versus its average, reflecting heightened investor interest. The stock's 52-week range is approximately $1.20 - $3.50.